National Bank of Canada
SKYE icon

National Bank of Canada’s Skye Bioscience SKYE Stock Holding History

National Bank of Canada’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242 Hold
400
– – ﹤0.01% 2786
2025
Q4 		$295 Buy
+400
New +$584 ﹤0.01% 2726

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

National Bank of Canada's SKYE Position: Q1 2026 in Review

National Bank of Canada held its Skye Bioscience (SKYE) position steady in Q1 2026 at 400 shares worth $242. The position accounts for ﹤0.01% of the portfolio, ranked #2786.

National Bank of Canada first reported a position in SKYE in Q4 2025 and has held it in 2 quarters since. The position peaked at $295 in Q4 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • National Bank of Canada held 400 shares of Skye Bioscience worth $242 as of Q1 2026.
  • National Bank of Canada left its Skye Bioscience share count unchanged in Q1 2026.
  • Skye Bioscience made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2786 holding.
  • National Bank of Canada first reported a position in Skye Bioscience in Q4 2025 and has held it in 2 quarters since.
  • National Bank of Canada's Skye Bioscience position peaked at $295 in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.